Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 10933094

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10934550

    Immunotherapy of cancer

    Phio Pharmaceuticals Corp. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10927088

    Thymoquinone derivatives for treatment of cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10925971

    Methods of treating PRLR positive breast cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10918666

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 2021038684

    Compositions and Methods for Cancer Immunotherapy

    ALKERMES PHARMA IRELAND LTD [IE] · Granted Thu Feb 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Feb 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10912797

    Tumor infiltrating lymphocytes and methods of therapy

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10912776

    Methods of treating cancer

    Corvus Pharmaceuticals, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10912741

    Prevention of liver cancer with safranal-based formulations

    UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. CA 3147876

    DERIVES DE LA 1,2,4-OXADIAZOL-5-ONE POUR LE TRAITEMENT DU CANCER

    BASILEA PHARM INT AG [CH] · Granted Thu Feb 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10899710

    Pyridines and their use in the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10898478

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 2021015826

    ANTICANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY

    BERLIN CHEMIE AG [DE] · Granted Thu Jan 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jan 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10894063

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10894044

    Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10888618

    Method of treating cancer

    Intensity Therapeutics, Inc. · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10889637

    Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies

    The Board of Regents of the University of Texas System · Granted Tue Jan 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10883994

    Identification of cancer stem cells markers and use of same for diagnosis and treatment

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10881689

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10881653

    Tricyclic compounds and their use in the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10881646

    Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers

    Biomed Valley Discoveries, Inc. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10875903

    Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10874631

    Altertoxin II as a selective inhibitor of Ewing family of tumor cells

    The Board of Regents of the University of Texas System · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10874610

    Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer

    Northwestern University · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. LT 3254695

    COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

    ASTELLAS PHARMA INC [JP] · Granted Mon Dec 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Sun Dec 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10870854

    Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

    The Board of Regents of the University of Texas System · Granted Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10869863

    Multi-arm polymeric targeting anti-cancer conjugate

    BrightGene Bio-Medical Technology Co., Ltd. · Granted Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. WO 2020249818

    PROCÉDÉ DE TRAITEMENT DU CANCER PAR DÉPÔT INTRATUMORAL DE MICROPARTICULES RADIOACTIVES

    ADVANCED ACCELERATOR APPLICATIONS [FR] · Granted Thu Dec 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Dec 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10857174

    Morpholino oligonucleotides useful in cancer treatment

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10857225

    Smallpox vaccine for cancer treatment

    Calidi Biotherapeutics, Inc. · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10857184

    Materials and methods for engineering cells and uses thereof in immuno-oncology

    CRISPR THERAPEUTICS AG · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10849875

    Cancer specific lipid targeted peptidomimetics

    The Board of Regents of the University of Texas System · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10849912

    Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10849960

    Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10845366

    Predictive markers for polyamine inhibitor cancer therapies

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10844052

    LLS compounds for treatment of cancer

    The Regents of the University of California · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10842835

    Oncolytic vaccinia virus mutants and using same for cancer treatment

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10835604

    Biomaterials for combined radiotherapy and immunotherapy of cancer

    Northwestern University · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10836759

    Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10828255

    Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents

    The Regents of the University of California · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10828280

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Granted Tue Nov 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10822588

    Agents and methods to elicit anti-tumor immune response

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10821163

    Process for the production of a DNA vaccine for cancer immunotherapy

    Vaximm AG · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10815484

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10815455

    Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1

    Vaximm AG · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10813952

    NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10813929

    Treating cancer with ATR inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10813909

    Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer

    The Regents of the University of California · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.